TITLE

Review: Angiotensin-receptor blockers and angiotensin-converting enzyme inhibitors have the lowest risk for diabetes: COMMENTARY

AUTHOR(S)
Padwal, Raj
PUB. DATE
May 2007
SOURCE
ACP Journal Club;May/Jun2007, Vol. 146 Issue 3, p73
SOURCE TYPE
Academic Journal
DOC. TYPE
Editorial
ABSTRACT
The author comments on a study on the relative odds of developing diabetes with the long-term use of various types of antihypertensive drugs in patients with hypertension or other cardiovascular risk factors. He asserted that the study should be viewed as associative since these are based on the data from secondary analyses of randomized controlled trials. He cited three points in interpreting the results of the studies in this field.
ACCESSION #
25169124

 

Related Articles

  • Treatment of Prehypertension in Diabetes and Metabolic Syndrome. Segura, Julian; Ruilope, Luis M. // Diabetes Care;Nov2009 Supplement, Vol. 32, pS284 

    The article explores the benefits of treating prehypertension in patients with diabetes and/or metabolic syndrome. It mentions that patients with elevated blood pressure (BP) and metabolic syndrome tend to be at great cardiovascular risk. The European Guidelines recommend antihypertensive...

  • Should White-Coat Hypertension in Diabetes Be Treated? Pro. Mancia, Giuseppe; Sega, Roberto; Bombelli, Michele; Quarti-Trevano, Fosca; Facchetti, Rita; Grassi, Guido // Diabetes Care;Nov2009 Supplement, Vol. 32, pS305 

    The article examines the rationality of treating white coat hypertension in diabetes. White coat hypertension refers to a condition in which clinic blood pressure repeatedly registers ≥140 millimeters of mercury (mmHg) systolic or 90 mmHg diastolic. The link between white coat hypertension...

  • UK doctors slow to utilize combination therapy for hypertension.  // PharmaWatch: Monthly Review;Jan2005, Vol. 4 Issue 1, p15 

    The article reports on the failure of doctors in Great Britain to fully recognize the therapeutic benefits of combined treatment approach in treating hypertension. Research studies showed that majority of hypertension sufferers are not fully controlled on a single antihypertensive therapy. Many...

  • Hora de elegir. Toledo, Rafael Bravo // AMF: Actualización en Medicina de Familia;2010, Vol. 6 Issue 7, p415 

    No abstract available.

  • Coming together: The ESC and EASD's new joint guidelines. Vora, Jiten // Diabetes Digest;2014, Vol. 13 Issue 1, p48 

    The article focuses on the cooperation of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD) in producing guidelines which represents an important move towards common sense. It states that the guidelines is a compilation of existing data in...

  • Pharmacologic and Nutritional Treatment of Mild Hypertension: Changes in Cardiovascular Risk Status. Oberman, Albert; Wassertheil-Smoller, Sylvia; Langford, Herbert G.; Blaufox, M. Donald; Davis, Barry R.; Blaszkowski, Thomas; Zimbaldi, Neal; Hawkins, C. Morton // Annals of Internal Medicine;1/15/90, Vol. 112 Issue 2, p89 

    Evaluates the changes in cardiovascular risk as a function of diet and drug therapy for mild hypertension. Efficacy of alternative regimens in treating mild hypertension; Influence of antihypertensive drugs on risk factors for cardiovascular disease; Changes in risk factor indices for...

  • Improved Outcomes with Antihypertensive Medication in the Elderly with Isolated Systolic Hypertension. Wang, J-G.; Staessen, J.A. // Drugs & Aging;2001, Vol. 18 Issue 5, p345 

    Isolated systolic hypertension affects over 15% of all individuals aged >60 years. In the elderly, systolic hypertension is a major modifiable cardiovascular risk factor. Systolic blood pressure (SBP) is associated with higher risk of an adverse outcome, whereas diastolic blood pressure (DBP) is...

  • Antihypertensive Therapy in Patients Undergoing Noncardiac Surgery. DeQuattro, Vincent; Deping Li // Journal of Cardiovascular Pharmacology & Therapeutics;Dec1997, Vol. 2 Issue 4, p331 

    The author focuses on the role of antihypertensive therapy in patients undergoing noncardiac surgery. About 10% of thirty-one million surgical patients in the U.S. annually are reportedly at an increased risk for perioperative and postoperative cardiovascular morbidity thus, presurgical...

  • The challenge of managing hypertension in chronic renal disease. Jain, Poorva; McManus, Richard J. // Journal of Renal Nursing;2011, Vol. 3 Issue 2, p58 

    Poorva Jain and Richard McManus look at hypertension in the general population and in patients with chronic kidney disease. They give an overview of the findings of all the major trials undertaken on blood pressure and chronic kidney disease over the last 10 years, outlining current blood...

  • Aliskiren: A Novel, Orally Active Renin Inhibitor. Saleem, T. S. Mohamed; Jain, A.; Tarani, P.; Ravi, V.; Gauthaman, K. // Systematic Reviews in Pharmacy;Jan2010, Vol. 1 Issue 1, p93 

    Renin-angiotensin-aldosterone systems play a major role in the regulation of human homeostasis mechanism, which are also involved in the development of hypertension and end-organ damage through activation of angiotensin II. Inhibitors of the renin-angiotensin-aldosterone system may reduce the...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics